Stricter global intellectual property rules are threatening generic versions of antiretroviral (ARV) treatments manufactured in India and other developing countries, PlusNews reports. Patents for first-line ARVs have expired, making them free to produce, but the newer and more effective drugs are out of reach to less developed nations. A group of nongovernmental organizations has filed a complaint to the United Nations saying patent restrictions are a violation to international rights to health.

To read the PlusNews article, click here.